Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor versus physician's choice in previously treated myelofibrosis
CTR20221489Phase 2Suspended
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor in myelofibrosis (MF), sponsored by Karyopharm Therapeutics Inc.. Started Aug 2022; status: suspended.
02
Drugs
selinexor
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on CTR20221489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221489.